Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd.
